Community Practice Considerations: Emerging Bispecific Antibodies in NHL
Post-Test/Evaluation

Exit Survey
Questions marked with a * are required
26%
Contact Information
Credentials/Degree (MD, DO, RN, etc.)
Date of  Participation
Which of the following is not a CD20/CD3 bispecific antibody in late-phase clinical testing for Non-Hodgkin’s Lymphoma (NHL)? 
Which of the following therapies is FDA-approved for the 2nd line treatment of R/R large B-cell lymphoma? 
A 66-year-old woman diagnosed with follicular lymphoma transformed into high-grade B-cell lymphoma, treated with DA-EPOCH-R x six cycles, and maintenance rituximab. She then progressed and received axi-cel, which was complicated by grade 4 CRS and grade 2 ICANS. She then progressed again 2 months after axi-cel and received pola-BR. Unfortunately, she developed progressive disease during her second cycle with pola-BR. Which of the following therapies would you recommend next? 
The most common adverse event in clinical trials evaluating bispecific antibodies was: (LO3)
Powered by QuestionPro